Zura Bio Ltd
zurabio.comWhat Do They Do?
Develops antibody drug candidates for patients with autoimmune and inflammatory diseases, including hidradenitis suppurativa and systemic sclerosis.
10-K for FY2025, filed Mar 19, 2026We are a clinical-stage biotechnology company developing novel and differentiated medicines for patients with autoimmune and inflammatory…View ↗
We have in-licensed three clinical-stage product candidates:View ↗
Tibulizumab is a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 19, 2026
How Are They Changing?
-
Apr 23, 2026
The chief financial officer departed and a new finance officer was appointed
Eric Hyllengren left; Marlyn Mathew became principal financial and accounting officer.
Sources
8-K, filed Apr 23, 2026
On April 20, 2026, Eric Hyllengren, the Company’s Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer…View ↗
From blank-check company to drug development The older report described JATT as having no operations and being formed to complete a business combination; the latest describes Zura as developing antibody medicines for autoimmune and inflammatory diseases.
Loading...
